GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including both anti-cancer and antiviral drugs. Its stock price is highly volatile and driven by news about the progress of clinical trials for its various developments.
Share prices of companies in the market segment - Cancer cure
Sunshine Biopharma is a diversified pharmaceutical company developing both antiviral and oncology drugs. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors value biotech companies with a broad pipeline.
Broad Market Index - GURU.Markets
Sunshine Biopharma is a pharmaceutical company developing drugs for the treatment of oncological and viral diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SBFM - Daily change in the company's share price Sunshine Biopharma
Sunshine Biopharma, Inc.'s daily price change reflects the extreme volatility inherent in oncology companies. It reflects investor reactions to clinical trial news, an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral diseases. The biotech sector, particularly oncology, is known for its high volatility. The chart below reflects the average fluctuations in this industry, providing context for evaluating SBFM stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Sunshine Biopharma is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sunshine Biopharma
Sunshine Biopharma's year-to-date performance tells the story of its diversified portfolio. Its 12-month market cap reflects both the progress of its oncology drug development and the sales of its nutritional supplements. Its valuation is a bet that at least one of its businesses, particularly antiviral, will succeed.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech company, Sunshine is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sunshine Biopharma, a pharmaceutical company with a diversified portfolio including oncology and antiviral drugs, exemplifies a risk-mitigation strategy. Its year-over-year market capitalization performance reflects how investors view its various programs and the ability to achieve commercial success at any one of them.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sunshine Biopharma
Sunshine Biopharma is a diversified pharmaceutical company. Its monthly performance reflects the combined impact of news on its oncology and antiviral programs. Progress in either program can significantly impact its valuation.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including oncology drugs and nutraceuticals. The company is also working on antiviral drugs. Assessing its prospects requires analyzing each of its segments. The pharmaceutical sector chart provides only a general overview of this diverse, yet small, company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sunshine Biopharma is a pharmaceutical company with developments in both oncology and antiviral technologies. A diversified portfolio can mitigate risks, but the stock's performance is still driven by news about clinical trials. Its correlation with the market is weak; the price reflects the sum of expectations for the entire development portfolio.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sunshine Biopharma
Sunshine Biopharma, a pharmaceutical company with developments in oncology and antiviral drugs, exhibits high volatility. Its weekly share price movements are a direct response to the release of clinical or preclinical trial data, which is typical for the speculative biotech sector.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company working on oncology and antiviral drugs. Its shares, like many biotech companies, are awaiting clinical trial results. The chart allows us to separate the impact of specific company news from general industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sunshine Biopharma is an oncology and antiviral company. Its shares are steeped in clinical trials and scientific data. The chart demonstrates how its performance depends solely on internal news, not on overall market movements.
Market capitalization of the company, segment and market as a whole
SBFM - Market capitalization of the company Sunshine Biopharma
Sunshine Biopharma's market capitalization is a measure of investors' valuation of its diversified portfolio. The chart shows the market's overall confidence in its oncology drugs and dietary supplements. Its high volatility and low price reflect both the risks of biotech development and competition in the dietary supplement market.
SBFM - Share of the company's market capitalization Sunshine Biopharma within the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio. Its market share is small, but its strategy includes both oncology drug development and nutraceutical sales. Market capitalization is the combined market valuation of these two distinct businesses.
Market capitalization of the market segment - Cancer cure
This chart shows the total value of the entire oncology sector. For Sunshine Biopharma, which develops cancer treatments, this line illustrates the scale of the battle against the disease. The rising chart reflects billions of dollars invested in new treatments and demonstrates the enormous and competitive market the company is targeting.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, ranging from oncology to antiviral drugs. Its market capitalization is the combined value of its various scientific programs and developments.
Book value capitalization of the company, segment and market as a whole
SBFM - Book value capitalization of the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company developing treatments for cancer and viruses. Its book value is its financial resources for research. It consists of cash that allows the company to conduct clinical trials. How has this research budget changed? The chart below shows.
SBFM - Share of the company's book capitalization Sunshine Biopharma within the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company. Its development of oncology and antiviral drugs requires a material base: in-house or contract laboratories and manufacturing facilities. The chart shows the company's share of the physical R&D and manufacturing infrastructure in this sector.
Market segment balance sheet capitalization - Cancer cure
Sunshine Biopharma is a pharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Sunshine focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Sunshine Biopharma's assets are a diversified portfolio, encompassing both anti-cancer drug development and over-the-counter nutritional supplement sales. The book value reflects the resources devoted to these diverse areas. The chart illustrates the scale of this small biopharmaceutical company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including oncology and antiviral drugs. Its market capitalization is a composite investor assessment of the success rate of its various developments.
Market to book capitalization ratio in a market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing treatments for cancer and viruses. Its high valuation on this chart reflects its strong scientific pipeline. Investors are buying not current assets, but the hope of developing a new, effective drug.
Market to book capitalization ratio for the market as a whole
Sunshine Biopharma is a pharmaceutical company focused on oncology. Its market capitalization reflects the hopes for the success of its cancer drugs. This chart demonstrates how willing investors are to invest in risky biotech projects with potentially huge returns.
Debts of the company, segment and market as a whole
SBFM - Company debts Sunshine Biopharma
Sunshine Biopharma, a pharmaceutical company with a diversified portfolio including oncology drugs and nutraceuticals, is raising capital to fund its clinical research and commercial activities. This chart reflects its funding strategy for advancing multiple products simultaneously.
Market segment debts - Cancer cure
Sunshine Biopharma is a pharmaceutical company active in several areas, including anti-cancer and antiviral drug development. This chart shows how the diversified biotech manages its capital by distributing it across various, unrelated, risky R&D programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including oncology and antiviral drugs. Developing multiple candidates simultaneously requires significant financial resources. This chart shows how the company uses debt to finance its extensive and capital-intensive clinical programs.
Market segment debt to market segment book capitalization - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing both oncology and antiviral drugs. Working in multiple areas increases its financial needs. This chart shows how the company finances its diverse research, comparing its debt to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Sunshine Biopharma is a pharmaceutical company developing both oncology and antiviral drugs. Its diversified research portfolio requires significant and consistent funding. Does the company raise debt? This graph of total debt in the economy allows you to assess its financial strategy and dependence on external capital.
P/E of the company, segment and market as a whole
P/E - Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company developing cancer treatments and antiviral agents. This chart shows how investors value its diversified pipeline. The valuation is volatile and depends on news about the progress of clinical trials in various areas.
P/E of the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing anti-cancer and anti-viral drugs. This chart illustrates the average valuation in the oncology and anti-viral development sector, where both the risks of clinical trials and the potential rewards of success are high.
P/E of the market as a whole
Sunshine Biopharma is a pharmaceutical company developing oncology and antiviral drugs. Its portfolio includes both traditional small molecules and mRNA technologies. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether SBFM's valuation reflects confidence in its diversified portfolio or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with two distinct businesses: cancer drug development and nutritional supplements. The company's valuation depends on the prospects of both segments. This chart reflects investors' combined expectations for the success of its oncology developments and sales growth in the nutritional supplements segment.
%20P%2FE%20Sunshine%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sunshine-Biopharma&v=1772652239807 "Chart of the company's future (projected) P/E Sunshine Biopharma")
Future (projected) P/E of the market segment - Cancer cure
Sunshine Biopharma is a diversified pharmaceutical company focused on both cancer treatments and dietary supplements. The chart compares Sunshine's expected future returns with those of its sector. It allows one to assess how the market views its diversified strategy and evaluates the potential of its key developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772652239849 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral diseases. Like many biotech companies, its valuation depends on the success of clinical trials. This overall risk appetite chart is an indicator of the market's willingness to finance risky but potentially highly profitable medical projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772652239867 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including both anti-cancer and antiviral drugs. Its financial metrics reflect clinical trial expenses across multiple areas. This chart illustrates the financial trajectory of a company pursuing success in multiple therapeutic areas.
Profit of companies in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing both anti-cancer and antiviral drugs. A diversified pipeline mitigates risks. This chart shows the overall profitability of the cancer and viral disease treatment sector, where there is a constant need for new, more effective drugs.
Overall market profit
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral diseases. Its prospects depend entirely on the success of clinical trials. The demand for new cancer and viral drugs is independent of the economic situation, making the company's business immune to the cycles illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including oncology and antiviral drugs. Future profits depend on the success of clinical trials across several areas. This chart aggregates analyst expectations across all of its programs, from cancer treatment to infection control.
%20profit%20of%20the%20company%20Sunshine%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sunshine-Biopharma&v=1772652239917 "Graph of future (projected) profit of the company Sunshine Biopharma")
Future (predicted) profit of companies in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio that includes both anti-cancer drugs and nutraceuticals. The company is also developing antiviral agents. This chart shows revenue forecasts for the oncology and pharmaceutical sectors, providing context for evaluating Sunshine Biopharma's strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772652239943 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Sunshine Biopharma is a pharmaceutical company developing drugs to treat oncological and viral diseases. Its future depends on the success of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772652239975 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company working on both anti-cancer and antiviral drugs. Revenue is generated from a variety of sources. This chart shows how investors view its diversified pipeline and the potential of each area.
P/S market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral infections. Its portfolio includes both traditional small molecules and innovative mRNA therapies, diversifying its scientific approaches. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Sunshine's pipeline.
P/S of the market as a whole
Sunshine Biopharma is a pharmaceutical company developing both antiviral drugs and new cancer treatments. This chart highlights that the valuation of diversified biotech companies depends on the combined potential of their R&D pipeline, and comparing them to the market can reveal whether investors believe in their scientific approach.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company developing both antiviral and anticancer drugs. The company's future revenue estimates for such a diversified portfolio reflect expectations across all areas. The chart shows how investors assess the overall potential of its drug candidates and the likelihood of their success in clinical trials.
%20P%2FS%20Sunshine%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sunshine-Biopharma&v=1772652240150 "The graph of the company's future (projected) P/S Sunshine Biopharma")
Future (projected) P/S of the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing anti-cancer and antiviral drugs. This chart reflects how investors assess the company's future earnings relative to the pharmaceutical sector. It demonstrates the market's confidence in its scientific developments, including potential treatments for various types of cancer and viral infections, and their prospects in clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772652240158 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Sunshine Biopharma is a pharmaceutical company with two core businesses: antiviral and oncology drug development. A diversified portfolio is a risk-mitigation strategy. This graph of investors' overall expectations reflects their view of the biotech sector, where multiple programs can increase the chances of ultimate success.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772652240187 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sunshine Biopharma
For Sunshine Biopharma, this metric reflects revenue that can come from both sales of its nutraceutical products and progress in oncology drug development. Its diversified model allows the company to generate revenue while simultaneously pursuing costly biotech research.
Sales of companies in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company with two distinct businesses: oncology drug development and nutritional supplements. Its revenue breakdown reflects the contribution of each segment, allowing for an assessment of how the company balances long-term biotech research with ongoing consumer product revenue.
Overall market sales
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral diseases. Its success depends entirely on clinical trial results and regulatory approval. This overall economics chart has no bearing on the valuation of a company whose mission is to create life-saving medicines.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company developing drugs for the treatment of cancer and viral diseases. Its portfolio includes both traditional and innovative approaches. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its oncology and antiviral drug candidates.
%20sales%20of%20the%20company%20Sunshine%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sunshine-Biopharma&v=1772652240273 "Schedule of future (projected) sales of the company Sunshine Biopharma")
Future (projected) sales of companies in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral infections. This chart shows revenue forecasts for the entire oncology market. Is growth expected due to the development of new drug classes and expanded access to treatment? This reflects the overall potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772652240278 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Sunshine Biopharma is a pharmaceutical company developing cancer treatments. Its success depends entirely on clinical trial results and regulatory approval. The demand for effective oncology drugs is independent of economic conditions, so this chart, which reflects consumer spending, is not relevant to the company's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772652240290 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company developing both oncology and antiviral drugs. This chart shows its financial trajectory through clinical development. Profitability depends on the success of its diversified portfolio and the ability to bring at least one of its candidates to market, which requires significant investment and time.
Market segment marginality - Cancer cure
Sunshine Biopharma, Inc. is a pharmaceutical company developing both antiviral and oncology drugs. This chart reflects the financial position of the company with a diversified early-stage portfolio, where profitability depends on clinical trial success across multiple pipelines.
Market marginality as a whole
Sunshine Biopharma is a pharmaceutical company developing anti-cancer and antiviral drugs. Its future depends on the results of clinical trials. This total return chart reflects the investment climate. In a healthy economy, investors are more inclined to fund risky but socially significant biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company with a diversified portfolio, including cancer treatments and antiviral agents. Its staff consists of scientists and managers managing various programs. This chart shows how the company allocates resources between its oncology research and generics production.
Share of the company's employees Sunshine Biopharma within the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing both antiviral and oncology drugs. Managing multiple R&D programs requires a significant scientific team. This graph shows the company's share of the biotech labor market, reflecting the breadth of its research activities and the size of its team of scientists and developers.
Number of employees in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing both anti-cancer and antiviral drugs. The chart shows its presence in the oncology sector. Its diversified portfolio allows the company to address several pressing healthcare challenges, including the treatment of aggressive forms of cancer.
Number of employees in the market as a whole
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viruses. Its growth depends entirely on success in research and clinical trials. This chart illustrates common economic cycles, placing Sunshine Biopharma in the world of science, where employment is an investment in the future of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sunshine Biopharma (SBFM)
Sunshine Biopharma is a diversified pharmaceutical company working on cancer treatments and antiviral agents. This chart shows how the market values their diverse pipeline. It reflects market capitalization per employee, which is the combined value of their intellectual property across multiple areas.
%20of%20the%20company%20Sunshine%20Biopharma%20(SBFM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sunshine-Biopharma-SBFM&v=1772652240759 "Chart of market capitalization per employee (in thousands of dollars) of the company Sunshine Biopharma (SBFM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Sunshine Biopharma (SBFM) is a pharmaceutical company developing drugs to treat cancer and viruses. This biopharma chart shows how the market values its research. The dynamics of this indicator may reflect progress in clinical trials: positive results can lead to a sharp increase in the valuation of each member of the research team.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772652240814 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Sunshine Biopharma is a pharmaceutical company developing drugs to treat cancer and viral infections. Its valuation, like that of other biotech companies, is determined by its pipeline. The chart shows a high valuation per employee, as the market is pricing in the potential success of its clinical programs, which could generate billions in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772652240841 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sunshine Biopharma (SBFM)
Sunshine Biopharma is a diversified pharmaceutical company working on both oncology and antiviral drugs. This chart shows how successful the company is. It reflects how much profit (or loss) the team of scientists and managers generates from their R&D projects and the commercialization of nutraceuticals.
%20Chart%20Sunshine%20Biopharma%20(SBFM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sunshine-Biopharma-SBFM&v=1772652240878 "Company Profit Per Employee (in thousands of dollars) Chart Sunshine Biopharma (SBFM)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Sunshine Biopharma is a pharmaceutical company developing cancer treatments and antiviral agents. In biotech, team performance is key to successful clinical trials. This chart shows the financial return per employee, allowing investors to assess the company's current stage and its potential.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772652240917 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Sunshine Biopharma is a pharmaceutical company. They have a diversified portfolio, ranging from oncology R&D projects to nutraceutical sales. It's a hybrid of risky biotech and stable retail. This chart helps us understand how this mixed model (R&D + sales) compares in terms of staff efficiency against the overall market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772652240950 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sunshine Biopharma (SBFM)
Sunshine Biopharma is a pharmaceutical company focused on oncology and antiviral drugs. This graph, like many biotech companies, reflects future potential. A sharp increase in revenue per employee will occur if their research is successfully commercialized, turning scientific advances into financial returns.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sunshine-Biopharma-SBFM&v=1772652240991 "Sales chart per company employee Sunshine Biopharma (SBFM)")
Sales per employee in the market segment - Cancer cure
Sunshine Biopharma is a diversified pharmaceutical company. They have both biotech development (cancer treatment) and a nutraceuticals (dietary supplements) division. This chart shows the average yield in the sector. For SBFM, this is an indicator of how productive their hybrid model (R&D + dietary supplement sales) is.
Sales per employee for the market as a whole
Sunshine Biopharma is a pharmaceutical company developing both anti-cancer and antiviral drugs. Currently, their focus is R&D. This chart reflects their clinical stage: the company is investing in research and does not yet have commercial revenue from sales.
Short shares by company, segment and market as a whole
Shares shorted by company Sunshine Biopharma (SBFM)
Sunshine Biopharma (SBFM) is a pharmaceutical company with a diversified portfolio, including both oncology drugs and dietary supplements. This chart tracks short positions. This "blurred" focus often attracts short sellers who doubt the seriousness of the company's R&D efforts.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sunshine-Biopharma-SBFM&v=1772652241038 "Short Shares Chart for the Company Sunshine Biopharma (SBFM)")
Shares shorted by market segment - Cancer cure
Sunshine Biopharma (SBFM) is a pharmaceutical company developing both antiviral drugs and oncology drugs (Adva-27a). This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism regarding the risks of clinical trials and the high mortality rate of projects in this sector.
Shares shorted by the overall market
Sunshine Biopharma is a biotech company focused on oncology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell, fearing the cash will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sunshine Biopharma (SBFM)
Sunshine Biopharma is a biotech company working on cancer and viral drugs. It's a classic R&D story. This graph is a "cardiogram" of clinical trials. It "overheats" to extremes with any positive data or approval news and "cools" during the long months of waiting.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sunshine-Biopharma-SBFM&v=1772652241082 "RSI 14 indicator chart for the company's stock Sunshine Biopharma (SBFM)")
RSI 14 Market Segment - Cancer cure
Sunshine Biopharma (SBFM) is a pharmaceutical company with two focuses: developing antiviral drugs and new cancer drugs. This is a highly speculative bet. This chart measures overall sentiment in the Oncology sector. It helps distinguish SBFM's trial success from overall "overheating" or "overselling" in the entire biotech sector.
RSI 14 for the overall market
For Sunshine Biopharma, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash spigot is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SBFM (Sunshine Biopharma)
Sunshine Biopharma is a diversified company. It develops oncology drugs (Adva-27a) and antiviral agents, and also has a dietary supplement division. This chart shows the speculative average target price from analysts, which reflects their "sum of the parts" valuation of this R&D portfolio and retail business.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SBFM-Sunshine-Biopharma&v=1772652241211 "A chart showing analyst consensus forecasts for the expected stock price. SBFM (Sunshine Biopharma)")
The difference between the consensus estimate and the actual stock price SBFM (Sunshine Biopharma)
Sunshine Biopharma is a diversified company. It develops innovative cancer drugs (Adva-27a) and also sells nutraceuticals. This chart shows the difference between the market valuation and the consensus estimate. It highlights the potential (and risks) analysts see in their oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SBFM-Sunshine-Biopharma&v=1772652241388 "A chart showing the difference between the consensus forecast and the actual stock price. SBFM (Sunshine Biopharma)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Sunshine Biopharma (SBFM) is a diversified pharmaceutical company developing both oncology and antiviral drugs (for the treatment of COVID-19). This chart shows general expectations for the cancer treatment sector. It reflects whether experts believe the company's R&D pipeline is successful.
Analysts' consensus forecast for the overall market share price
Sunshine Biopharma is a biotech company with a diversified portfolio, ranging from cancer treatments to antiviral drugs (COVID-19). This chart reflects the overall market "risk appetite." For Sunshine, a high-risk, broad-focus company, overall market optimism (risk appetite) is critical to raising the capital needed for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sunshine Biopharma
Sunshine Biopharma is a chameleon company. Their old business is oncology R&D (Adva-27a). Their new (hyped) business is antivirals (for COVID) and (speculatively) nutraceuticals (dietary supplements). This chart is a summary indicator of their fuzzy strategy. It reflects their (very risky) R&D pipeline and their constant need to raise capital (dilution).
AKIMA Market Segment Index - Cancer cure
Sunshine Biopharma (SBFM) is a hybrid company. Their core business is robust R&D in oncology (developing anti-cancer drugs such as Adva-27a). They also operate a nutraceuticals (dietary supplement) division. This chart shows the segment's average index, helping investors assess how this dual-asset model compares to the industry average.
The AKIM Index for the overall market
Sunshine Biopharma is a pharmaceutical company that produces generics and develops its own anti-cancer drugs. This chart, which reflects the market average, provides a macro backdrop. It helps assess how SBFM, which combines generic revenue with R&D costs, compares to overall economic trends.
